肾细胞癌中Mina 53的表达及其与临床病理及预后的关系

Expression of Mina53 in renal cell carcinoma and its relationships with clinicopathological characteristis and prognosis

目的探讨肾细胞癌组织中Mina53的表达水平及其与临床病理及预后的关系。方法采用RT-PCR技术测定96例肾细胞癌组织及20例癌旁正常肾组织中Mina53的表达,免疫组化法测定其蛋白水平的表达,分析其结果与临床病理及预后的关系。结果 Mina53平均模板量在肾细胞癌组织中的表达明显高于正常肾组织的表达(P<0.01),且在Ⅲ期、Ⅳ期肾细胞癌组织中的表达明显高于Ⅰ期、Ⅱ期的表达水平(P<0.01),Mina53蛋白在肾细胞癌组织中的表达水平明显高于其在正常肾组织的表达水平(P<0.01);Mina53高表达者的预后较低表达者明显要差(P<0.01)。结论 Mina53基因及蛋白的高表达与肾细胞癌临床病理分期有关,其表达水平越高,预后越差,Mina53有望成为预后判断的新指标。

Objective To study the expression of MinaS3 in renal cell carcinoma （RCC） and its relationships with clinicopathological characteristis and prognosis. Methods The expressions of MinaS3 mRNA were detected in RCC （n = 96） and normal renal tissues （n=20） by real-time fluorescent quantitative polymerase chain reaction （RT-PCR）, the product of RT-PCR was quantitated by comparative Ct method. The MinaS3 protein were detected by immunohistochemistry method in RCC tissues and normal renal tissues. Results RT-PCR showed that the average quantity of Mi na53 mRNA in RCC is significant higher than that in normal kidney tissues （P〈0.01）. The expression of Mina53 mRNA was significant higher in tissues of clinical stage Ⅲ or Ⅳthan that in stage Ⅰ or Ⅱ （all the P〈0.01）. The expression of MinaS3 protein was significant higher in tumor tissue than those in normal tissue （P〈0.01）. Mina53 expression in tumor were closely related to prognosis. The higher expression of Mina53, the poor prognosis （P〈0.01）. Conclusions The higher clinical stage and the poor prognosis may be related to higher expression of the Mina53 gene mRNA and protein. Mina53 may be a novel useful marker for prognosis of RCC.